Given these constraints, our preliminary experience with cellular immunotherapy showing a lack of efficacy in two out of three patients despite the addition of VEGF and PD-1 inhibition is in line with previous reports highlighting the difficulties in achieving an immune-mediated response in an otherwise “cold” tumor microenvironment seen in GI cancers. This evidence concerns the gene VEGFA and neoplasm.